Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits.
De Pasquale, M.d., de Ville de Goyet, J., Monti, L., Grimaldi, C., Crocoli, A., Castellano, A. (2017). Bevacizumab combined with chemotherapy in children affected by hepatocellular carcinoma: A single-center experience. ANTICANCER RESEARCH, 37(3), 1489-1493 [10.21873/anticanres.11475].
Bevacizumab combined with chemotherapy in children affected by hepatocellular carcinoma: A single-center experience
De Pasquale M. D.
Writing – Original Draft Preparation
;de Ville de Goyet J.Writing – Original Draft Preparation
;
2017-01-01
Abstract
Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
